----
Current ValuationThe current P/E ratio is -2.19, within the reasonable range, cheaper than 41% of the time in the past 3 years, and the industry ranks 22/38, the industry Median -0.84.
-2.19xP/E
$0.71Stock price
$-0.32Earnings per share
-2.19xP/E
Stock price$0.71Earnings per share$-0.32
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -2.36x
- Typical range
- -3.64x–-1.79x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
012243648
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
HTFLUSHeartFlow | -36.26x | 74.45% | $4.29B |
SDGRUSSchrodinger | -37.57x | 13.66% | $2.04B |
CERTUSCertara | -19.98x | 1,962.60% | $1.37B |
TDOCUSTeladoc | -5.69x | 22.88% | $1.01B |
MDRXUSVeradigm | -- | -- | $851.43M |
SOPHUSSophia Genetics SA | -7.53x | 19.83% | $608.66M |
EVHUSEvolent Health | -0.92x | 84.41% | $468.07M |
CTEVUSClaritev | -1.50x | 12.62% | $424.19M |
AMWLUSAmerican Well | -2.75x | 57.74% | $214.99M |
DHUSDefinitive Healthcare | -0.84x | 28.60% | $140.54M |
LFMDUSLifeMD | -46.29x | 195.82% | $134.48M |
HCATUSHealth Catalyst | -0.50x | 4.22% | $132.45M |
DRIOUSDarioHealth | -8.51x | 62.43% | $59.54M |
RNLXYUSRENALYTIX PLC SPON ADS EACH REP 50 ORD (POST SPLIT) | -2.31x | -- | $45.89M |
ITOCUSiTonic | -3.41x | -- | $30.36M |
ONMDUSOneMedNet | -3.45x | -- | $29.11M |
AIFFUSFirefly Neuroscience | -2.03x | -- | $19.14M |
BFRGUSBullfrog AI | -2.19x | 41.27% | $13.14M |
HCTIUSHealthcare Triangle | -0.50x | 93.28% | $8.44M |
SCNXUSScienture | -0.18x | 91.48% | $6.78M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
